| Biotechnology Industry | Healthcare Sector | Mr. Jonathan M. N. Rigby M.B.A., MBA CEO | XETRA Exchange | CA81752F1062 ISIN |
| Canada Country | - Employees | - Last Dividend | 27 May 1999 Last Split | - IPO Date |
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company based in Canada. The organization is primarily focused on advancing the development and commercialization of cutting-edge regenerative medicine therapeutics. Among its key innovations is the proprietary Cell Pouch, a unique medical device designed to create a natural environment within the body, which supports the housing, survival, and functionality of therapeutic cells. These cells are essential as they release critical proteins or factors that may be deficient in patients suffering from chronic diseases, offering an innovative alternative to the traditional regimen of daily drug administration. Additionally, Sernova Corp. collaborates with the University of Miami through a research agreement to enhance the development of Conformal Coating Technology, which is integrated with therapeutic cells within the Cell Pouch. Established in 1998, Sernova Corp. is headquartered in London, Canada.
The Cell Pouch is an innovative implantable medical device that creates an ideal natural environment within the body for therapeutic cells. It is designed to ensure the long-term survival and function of these cells, enabling them to release vital proteins or factors that the body may be lacking, thus providing therapeutic benefits to patients with chronic illnesses.
This technology is developed in partnership with the University of Miami and is designed to work alongside therapeutic cells in the Cell Pouch. Conformal Coating Technology enhances the protective measures for therapeutic cells, safeguarding them against the body’s immune system. This collaboration aims to improve the efficacy and longevity of the treatments facilitated by the Cell Pouch.
Sernova Corp. is committed to the development of various regenerative medicine therapeutics focused on treating chronic diseases. The therapeutics are designed to either replace or augment the missing factors in patients' bodies, aiming to reduce dependency on conventional drug therapies and improve patients' overall quality of life.